Open Access

Mechanistic investigations of antitumor activity of a Rhodamine B‑oleanolic acid derivative bioconjugate

  • Authors:
    • Ioana Macașoi
    • Ioana Zinuca Pavel
    • Alina Elena Moacă
    • Ștefana Avram
    • Vlad Laurențiu David
    • Dorina Coricovac
    • Alexandra Mioc
    • Demetrios A. Spandidos
    • Aristidis Tsatsakis
    • Codruța Șoica
    • Victor Dumitrașcu
    • Cristina Dehelean
  • View Affiliations

  • Published online on: June 26, 2020     https://doi.org/10.3892/or.2020.7666
  • Pages: 1169-1183
  • Copyright: © Macașoi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Cancer remains a major health problem worldwide due to its high mortality rate. New therapeutic options highlight the importance of discovering new compounds that target the tumor microenvironment, interrupt angiogenesis and act selectively. The present study assessed the antitumor effect and investigated the mechanism of action of a rhodamine B‑conjugated oleanolic acid derivative (RhodOA). Consequently, the compound was tested on different human tumor cell lines (A375 melanoma, A549 lung adenocarcinoma and MDA‑MB‑231 breast adenocarcinoma) and on a non‑tumor cell line HaCaT human keratinocyte. RhodOA produced a dose‑dependent decrease in tumor cell viability especially in the melanoma cells while affecting the keratinocytes less. In melanoma cells, RhodOA reduced cell migration and produced condensation of cell nuclei and of actin fibers. Furthermore, an impairment in melanoma cell mitochondrial function was observed, while the mitochondrial function of keratinocytes was left intact. In the in ovo chorioallantoic membrane model, RhodOA elicited antiangiogenic effect, without showing irritation effect on the membrane. The study provides information on the selective antitumor effect of the derivative and its ability to inhibit cellular respiration, therefore RhodOA can be classified as ‘MITOCAN’.
View Figures
View References

Related Articles

Journal Cover

September-2020
Volume 44 Issue 3

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Macașoi I, Pavel IZ, Moacă AE, Avram Ș, David VL, Coricovac D, Mioc A, Spandidos DA, Tsatsakis A, Șoica C, Șoica C, et al: Mechanistic investigations of antitumor activity of a Rhodamine B‑oleanolic acid derivative bioconjugate. Oncol Rep 44: 1169-1183, 2020
APA
Macașoi, I., Pavel, I.Z., Moacă, A.E., Avram, Ș., David, V.L., Coricovac, D. ... Dehelean, C. (2020). Mechanistic investigations of antitumor activity of a Rhodamine B‑oleanolic acid derivative bioconjugate. Oncology Reports, 44, 1169-1183. https://doi.org/10.3892/or.2020.7666
MLA
Macașoi, I., Pavel, I. Z., Moacă, A. E., Avram, Ș., David, V. L., Coricovac, D., Mioc, A., Spandidos, D. A., Tsatsakis, A., Șoica, C., Dumitrașcu, V., Dehelean, C."Mechanistic investigations of antitumor activity of a Rhodamine B‑oleanolic acid derivative bioconjugate". Oncology Reports 44.3 (2020): 1169-1183.
Chicago
Macașoi, I., Pavel, I. Z., Moacă, A. E., Avram, Ș., David, V. L., Coricovac, D., Mioc, A., Spandidos, D. A., Tsatsakis, A., Șoica, C., Dumitrașcu, V., Dehelean, C."Mechanistic investigations of antitumor activity of a Rhodamine B‑oleanolic acid derivative bioconjugate". Oncology Reports 44, no. 3 (2020): 1169-1183. https://doi.org/10.3892/or.2020.7666